A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Venous leg ulcers are a common, costly and debilitating condition, with few effective treatments. Compression bandaging helps healing, but more than four out of every ten leg ulcers remain unhealed after three months. New treatments to help heal venous ulcers are urgently needed. Initial studies with a new drug product candidate called Nexagon® (developed by CoDa Therapeutics, Inc.) have shown improvements in healing when applied topically to a wound. Further research will be undertaken to assess the safety and activity of Nexagon® when applied to venous leg ulcers in humans, and to obtain further information on the most appropriate dose or doses to apply. A proposed randomised controlled trial aims to further evaluate Nexagon® by randomly allocating (e.g., by the toss of a coin) 90 people with venous leg ulcers to Nexagon® (one of two different doses) or a vehicle (substance containing no medication) to be applied to their ulcer three times over four weeks. Participants will be followed up for 12 weeks to evaluate ulcer healing.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of venous leg ulceration
Ankle brachial index of > 0.80 measured during screening or within three months prior to the Day -14 visit.
Reference ulcer area greater than 1 cm2 and less than 25 cm2
Reference ulcer present for at least 4 weeks
Have an ankle circumference of greater than 18 cm
Male of female patients aged 18 years or over
Able to tolerate effective compression bandaging
Patients able to walk independently with or without mobility aids
Able and willing to give informed consent
Able and willing to attend all follow up visits
Significant change in ulcer size in the screening period screening period
Presence of a non-study ulcer within 2.0 cm of the reference ulcer
Wound bed with exposed bone, tendon or fascia
Patients with leg ulceration etiology other than venous insufficiency
Patients who require wheel chairs for normal mobility
Patients who have any ulcer (reference or non-reference) which shows signs of clinical infection
Patients who have any ulcer (reference or non-reference) positive for β-hemolytic streptococcus upon culture.
Patients who are unable to tolerate or comply with the standardized compression bandaging protocol specified in this protocol
Female patients who are pregnant or breastfeeding.
Patients who are currently taking:
Oral corticosteroid therapy or topical corticosteroid on the leg where the reference ulcer is located
Growth factors (e.g. Regranex)
Cell cultures or topical skin factors
Renal insufficiency defined as an estimated GFR which is < 30 mL/min/1.7m2
Abnormal blood biochemistry defined as 3 times that of the upper limit of the normal range
Hepatic insufficiency defined as total bilirubin > 2 mg/dL or serum albumin < 25 g/L
HbA1c > 8.5%
Hemoglobin < 10 g/dL
Hematocrit < 0.30
Platelet count < 100,000
Patients have had a myocardial infarction within the previous 6 months or patients with unstable angina pectoris
Collagen vascular disease
Severe rheumatoid arthritis
Cellulitis or osteomyelitis
Patients who have, or are suspected of having malignancy, or who have received treatment for any active malignancy, apart from non-melanomatic skin cancer, within 3 months prior to treatment
Patients who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study, e.g., known to abuse alcohol or drugs currently or to have psychological disorders that could affect follow-up care